COIOS
Emergent technology Item refines preprint

AI on breast biopsy slides flagged intermediate-risk patients who gained from chemotherapy

Applied without retraining to 6,735 TAILORx trial participants, an AI model reading H&E slides alongside clinical variables predicted disease-free interval (C-index 0.736) and, within the intermediate-risk group, separated patients who gained from chemotherapy from those who did not.

A prespecified analysis of the TAILORx randomised trial applied an AI model reading H&E pathology slides alongside clinical variables to 6,735 node-negative, hormone receptor-positive breast cancer patients, with no TAILORx data used in training. The score was associated with disease-free interval in both treatment arms and remained significant after adjustment for the 21-gene Recurrence Score, and within the intermediate-risk group it identified a chemotherapy benefit (5 percentage points higher 5-year disease-free interval) that the genomic assay itself did not detect (interaction p=0.001 for the AI score against p=0.20 for the genomic score).

Why it is interesting: An externally validated, prespecified test of image-based AI as a predictive rather than merely prognostic marker, in a randomised trial where the genomic assay itself found no such interaction.

Source
medRxiv, 20 September 2026
DOI
10.64898/2026.09.12.26362500
Type
Preprint
Design
Prespecified secondary analysis of the TAILORx phase 3 randomised trial, 6,735 patients with H&E slides and 21-gene Recurrence Score, using an AI model not trained on trial data
Verdict
Refines prior evidence
Driver
AI in medicine
Driver
Cancer